- Key facts & figures
- Sanofi share
- Analysts / Vara Consensus
- Reports & publications
- Results & presentations
- Corporate governance
Annual General Meetings
- Our publications
- Being a shareholder
- Becoming a shareholder
- Shareholders committee
- U.S. investors
- Regulated information in France
- Get to know Sanofi
- Working at Sanofi
- Our Expertise, your future
- Join Sanofi
- Being our partner
- Understanding science discovering
- Developing and marketing innovative solutions
- Manufacturing and supply
- Healthcare Solutions
- Our approach
- Improving access to healthcare
- Working together
- Ethics and transparency
- Preserving the environment
- ‘LE HUB’ eMAG
You are here:
Fighting neglected tropical diseases
One billion people worldwide suffer from debilitating communicable diseases which occur exclusively in developing countries1. There is a pressing need to reduce the global impact of these “neglected” tropical diseases.
Through a partnership with the World Health Organisation, Sanofi has been actively engaged in the fight against these “neglected” tropical diseases since 2001, with a contribution of USD 100 million in financial support and drug donations for the period 2001-2020.
Thanks to this partnership with the WHO, 34 million people have been screened for sleeping sickness and around 200,000 patients have been diagnosed and treated for this disease, which is fatal if left untreated2. Since 2001, the number of identified cases has fallen by 89%, reaching less than 3,000 new cases in 2015, which is the lowest number ever recorded.
Because most of the current treatments are given by infusion and require hospitalization, Sanofi, in partnership with Drugs for Neglected Diseases initiative (DNDi), a non-profit drug research and development organization is developing a new oral treatment for sleeping sickness. All these initiatives aim to eliminate the disease by 20203.
Each year, 1.3 million new cases of leishmaniasis and 20,000 to 30,000 deaths due to the disease are reported. This parasitic disease transmitted by the bite of a sand fly, causes skin lesions and severe disability4.
In Brazil, Sanofi produces a drug against leishmaniasis which is provided at a preferential price in developing countries. More than 6 million doses were distributed in 20155.
Sanofi is also involved in combating Chagas disease and simplifying the treatment for Buruli ulcer.
For more information:
- WHO, “Sustaining the drive to overcome the global impact of neglected tropical diseases,” Second WHO report on neglected tropical diseases, 2014.
- WHO data, May 2016
- WHO, Accelerating work to overcome the global impact of neglected tropical diseases, 2012
- WHO, Media Center, Leishmaniasis Fact Updated April 2017
- Internal data, 2015
September 20, 2017
August 21, 2017